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Summary Ifosfamide is clinically used in combination chemotherapy regimens for the treatment of patients
with high-grade lymphomas, sarcomas and metastatic germ cell tumours. In order to reduce the
oxazophosphorine-related urothelial toxicity, sodium mercaptoethane sulphonate (mesna) is used in different
schedules following the administration ofifosfamide. The proposed mechanism of mesna activity is the binding
of toxic oxazaphosphorine metabolites such as acrolein in the urine of the patients. Since an influence of
mesna on ifosfamide anti-tumour activity is controversial, the current study has used xenografts from two
human testicular cancer cell lines heterotransplanted into nude mice to study the anti-tumour activity of
ifosfamide in combination with different dosages and schedules of mesna. In both human testicular cancer cell
lines, H 12.1 and 2102 EP, ifosfamide demonstrated anti-tumour activity as a single agent. No reduction in
ifosfamide activity was observed with the application of mesna at a dose range from 50% to 200% of the
ifosfamide dose. Furthermore, the application of mesna before and 3 h after ifosfamide, a schedule used in
many clincal protocols because of the short half life of mesna, not only maintained high ifosfamide
anti-tumour activity but also seemed to be associated with the lower systemic and urothelial toxicity of
ifosfamide therapy compared with ifosfamide given alone. In conclusion, the experimental in vivo system using
human heterotransplanted testicular cancer cell lines confirms the significant anti-tumour activity of ifosfamide
in malignant germ cell tumours and demonstrates that mesna does not impair ifosfamide anti-tumour activity
in this model. These results are most likely transferable to the use of mesna in patients with metastatic
testicular cancer.
The oxazophosphorine derivates cyclophosphamide and ifos-
famide are part of many different combination chemotherapy
regimens and have demonstrated anti-tumour activity in a
variety of malignant diseases, such as lymphomas, bone and
soft-tissue sarcomas and germ cell tumours (Loehrer et al.,
1986; Canabillas et al., 1987; Benjamin et al., 1993). Apart
from their haematological toxicity, damage to the urinary
tract leading to haemorrhagic cystitis is a major side-effect of
therapy with these agents. Philips et al. were the first to
describe the urothelial toxicity of cyclophosphamide as early
as 1961. They reported rapid changes including ulcerations,
haemorrhage and oedema in all bladder tissues in rats follow-
ing a single dose of cyclophosphamide. When reactive urine
from a cyclophosphamide-treated animal was introduced by
catheter into another animal which had not been exposed to
cyclophosphamide the same typical histological changes were
produced. These were the first observations suggesting that
bladder damage was a local response to contact by toxic
bladder urine.
The frequency of haemorrhagic cystitis following cyclo-
phosphamide or ifosfamide single-agent therapy is of the
order of 10-100%, depending on the dosage used (Morgan
et al., 1976; Wang et al., 1978). Different prophylactic
measures have been suggested to overcome this toxicity, such
as the use of a high fluid intake, promoting an active diuresis,
urine alkalinisation or instillation of agents containing sul-
phydryl groups into the bladder (Kovach et al., 1974; Bruhl
et al., 1976; Morgan et al., 1976, 1981).
With the availability of the mercaptoethane sulphonate
derivative mesna (sodium 2-mercaptoethane sulphonate), a
prophylactic agent with the potential for detoxification of
oxazaphosphorine metabolites in the urinary tract had come
into clinical use (Brock et al., 1984). In a single-blind
crossover trial seven of eight patients receiving 2 g m-2 twice-
weekly ifosfamide therapy developed haematuria in compari-
son with only one of eight patients who received additional
mesna with the same dose of ifosfamide (Bryant et al., 1980).
The proposed mechanism of mesna activity is the binding of
active oxazaphosphorine metabolites by sulphydryl groups,
which has been demonstrated in the case of the toxic meta-
bolite acrolein. Acrolein is spontaneously formed in the urine
from the primary metabolites eliminated via the kidneys
(Brock et al., 1979). Different clinical studies have demon-
strated the ability of mesna to reduce the incidence of
haemorrhagic cystitis when given concomitantly with the
oxazaphosphorine therapy (Bryant et al., 1980; Burkert,
1983; Pratt et al., 1989).
Although some clinical studies have demonstrated no
obvious interference of mesna application with the anti-
tumour activity of ifosfamide or cyclophosphamide, this pos-
sibility has been a major concern (Wagner et al., 1974;
Bryant et al., 1980; Burkert, 1983; Wist et al., 1987; Willemse
& de Vries, 1989). In order to address this question without
the limitations of clinical studies in patients a xenograft nude
mice tumour model was used. The transplantation of human
tumour tissue into congenitally athymic mice has been used
as a valid and reliable test system for in vivo evaluation of
chemotherapeutic drugs. The heterotransplanted tumours
preserve their histological and biological characteristics and
have already been successfully used for the investigation of
different cytostatic agents (Casper et al., 1987; Harstrick et
al., 1990). Therefore, the anti-tumour activity of different
schedules of ifosfamide and mesna application was studied in
two human heterotransplanted testicular cancer cell lines
transplanted into nude mice.
Materials and methods
Cell lines
The two human testicular germ cell tumour lines H 12.1 and
2102 EP were used for the experiments. H 12.1 was estab-
lished in our laboratory in 1981 from an orchiectomy speci-
men prior to chemotherapy. Cell line 2102 EP was estab-
lished by Dr Bronson, San Antonio, TX, USA, in 1977. The
origin and histology after heterotransplantation of both cell
lines are shown in Table I. The cell lines were grown as
continuous monolayer cultures in RPMI-1640 medium
supplemented with 15% fetal calf serum (Biochrom, Berlin,
Germany), penicillin 2 IU ml-', streptomycin 2 lag ml-' and
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L-glutamine 0.04 mmol I'. No significant changes in histo-
logy, cytogenetics, growth kinetics or response to chemo-
therapy over more than 70 passages were observed in these
cells. For the experiments cells from passages 70-80 of both
cell lines were used.
Mice
Male athymic (NU/NU) NMRI mice were used. They were
kept in pathogen-free conditions, fed on an autoclaved stan-
dard diet and given free access to sterilised water. Urine
collection using a self-developed microcontainer applied to
the genital area of the mice was attempted for microscopic
examination following the first 2 days after ifosfamide ap-
plication.
Drugs and treatment
Commonly available drug preparations were used: both ifos-
famide and mesna were gifts of ASTA Medica, Frankfurt,
Germany. Drug solutions were freshly prepared before
administration and given by intraperitoneal (i.p.) injections.
For ifosfamide 50% of the maximal tolerated dose (MTD)
equivalent to the lethal dose 20 (LD 20) were used. Ifos-
famide was given on days 1-4 and 15-18 at 50 mg kg-l day.
Different schedules of mesna applications were used. The
dosages and treatment schedules used, their toxicity and
anti-tumour activity are summarised in Table II.
Heterotransplantation and anti-tumour activity
The cells were harvested from culture bottles by trypsination
to obtain single-cell suspensions. The number of viable cells
was counted by trypan blue exclusion and the cells were
resuspended at 5 x IO viable cells per ml in normal growth
Table I Characteristics of human testicular cancer cell lines H 12.1
and 2102 EP
H 12.1 2102 EP
Primary establishment 21/5/1981 14/10/77
(J. Casper) (D. Bronson)
Primary histology of S, EC, CC, DT TC, YST
the testis tumour
Histology after EC, TC, STGC EC, STGC
heterotransplantation
Tumour marker production AFP, P-HCG AFP (P-HCG)
Doubling time in vivo 13.5 days 9 days
S, seminoma; EC, embryonal carcinoma; CC, chorioncarcinoma;
DT, differentiated teratoma; TC, teratocarcinoma; YST, yolk sac
tumour; STGC, syncytiotrophocytic giant cells.
medium. A 0.2ml volume of this suspension was injected
subcutaneously into the right flank of the mice. The tumours
were regularly measured and the cross-sectional area was
calculated (length x width). When the tumours had reached a
size of 1-1.5cm2 the mice were stratified by tumour size,
divided into comparable groups of 5-6 mice and started on
the protocol. After the start of treatment the tumours were
measured every 3 days and growth curves were plotted of the
relative tumour area (rTA) on given days. Thirty days after
the start of treatment anti-tumour activity was assessed by
calculating the relative tumour area reduction compared with
untreated control mice. For all groups, means ± standard
deviations were obtained. The groups were compared using
the Fisher exact test at a 5% significance level. For urothelial
toxicity microscopic examination of urine for haematuria was
attempted. Collected urine was centrifuged and the number
of red blood cells (RBC) per high-power microscopic field
was determined in the sediment (Addis count). Haematuria
was graded semiquantitatively as: none = 0-4 RBC, + = 4-10
RBC, + + = 10-20 RBC and + + + = >20 RBC or macro-
haematuria. As a further estimation of treatment toxicity
survival and body weight change data were used. Toxicity
results for both cell lines H 12.1 and 2102 EP were
pooled.
Results
Toxicity ofsingle agents
The MTD of ifosfamide had been determined in previous
experiments to be of the order of 100mgkg-'day-'
(Schmoll, 1989; Harstrick et al., 1990). For mesna given
alone concentrations ranging from 5 to 500mgkg-'day-'
were used. No significant toxicity was observed at all concen-
trations of mesna, resulting in survival of all mice and no
apparent anti-tumour activity of this agent. For the
experiments mesna at doses between 25 and 100 mg kg-'
day-' was used in conjunction with 50 mg kg' day-' ifos-
famide.
Toxicity ofifosfamide/mesna combination
For treatment regimens which used ifosfamide alone or ifos-
famide with single-bolus application of mesna at the start of
ifosfamide therapy between 37 and 40% of animals had died
at day 30. In contrast, schedules using ifosfamide followed by
bolus application of mesna at the start of ifosfamide therapy
and 3 h later showed a significantly decreased toxicity with
only 0-20% of animals dying prior to the end of the experi-
ment (Table II). This tendency could also be observed in the
data on body weight change with loss of weight in the range
Table II Schedule of ifosfamide/mesna application, toxicity (expressed as number of surving mice and body weight change) and
anti-tumour activity calculated as relative tumour area (rTA) in comparison with untreated control mice after 30 days
Toxicity Anti-tumour activity (rTA)
Survival Body weight
Schedule and dosage H 12.1 2102 EP Total (%) change (%) H 12.1 2102 EP
Control 5/5 5/6 94 -4 2 2.40 0.6 2.10 0.5
Ifosfamide 50mg kg-', i.p. on 3/5 4/6 63 - 15 5 0.80 0.4 1.40 0.5
days 1-4 and 15-18
Ifosfamide 50mgkg-', i.p. 3/5 ND 60 - 10 3 0.75 0.2 ND
Mesna 50mgkg-', i.p. on
days 1-4 and 15-18
Ifosfamide 50mgkg', i.p. 5/5 ND 100 -10±2 0.68±0.1 ND
Mesna 25mgkg-', i.p.
at 0 and 3 h on days 1-4
and 15-18
Ifosfamide 50mgkg-', i.p. 4/5 5/6 87 -4±4 0.50±0.2 1.10±0.3
Mesna 50mgkg-', i.p.
at 0 and 3 h on days 1-4
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of 10-15% for mice receiving ifosfamide therapy alone
compared with 4-10% for animals receiving ifosfamide in
combination with two bolus applications of mesna (no statis-
tically significant difference). This trend was observed in both
cell lines.
In 16 of 26 mice semiquantitative analysis of urine speci-
mens was possible. Mice receiving ifosfamide in combination
with two applications of mesna showed the lowest incidence
of haematuria (two of six mice with + haematuria) com-
pared with mice receiving only single-bolus mesna (two of
four mice with + haematuria). Of six mice receiving ifos-
famide without mesna and examined for erythrocytes in the
urine, two mice developed + haematuria, one mouse
developed + + haematuria and one mouse macroscopic
(+ + +) haematuria.
Anti-tumour activity ofifosfamide/mesna application
The anti-tumour activity of different therapy schedules ex-
pressed as the relative tumour area (rTA) during the 30 days
of the experiment for cell lines H 12.1 and 2102 EP is shown
in Figures 1 and 2 respectively. For both cell lines ifosfamide
as single-agent therapy showed significant anti-tumour
activity with growth retardation of the heterotransplanted
tumours. Treatment with ifosfamide alone and treatment
with all schedules of ifosfamide plus mesna application
resulted in a significant growth reduction of the tumours
compared with untreated control mice. In cell line H 12.1 the
highest anti-tumour activity was seen with ifosfamide in com-
bination with two bolus applications of mesna at the start of
ifosfamide therapy and repeated 3 h later. The application of
ifosfamide with mesna at doses from 25 mg kg-' at one time
point up to 50 mg kg-' at two different time points did not
significantly influence the anti-tumour activity of ifosfamide
in comparison with ifosfamide therapy given alone. For cell
line 2102 EP both treatment with ifosfamide and ifosfamide
plus mesna showed significant activity. No difference in anti-
tumour activity was seen between the use of ifosfamide alone
compared with ifosfamide with the same dose of mesna given
at different time points as bolus administration.
Discussion
Besides cisplatin and etoposide, ifosfamide is one of the most
active drugs used in the treatment of testicular cancer. Early
phase II studies in the mid-70s have indicated responses in
patients with relapsed disease (Schmoll et al., 1978). Since
that time similar anti-tumour activity of ifosfamide has been
demonstrated in both non-seminomatous and seminomatous
germ cell cancer, particularly in combination regimens with
cisplatin, bleomycin, vinblastine and etoposide (Schmoll,
1989). Ifosfamide has recently been incorporated into stan-
dard regimens for salvage therapy and experimental regimens
used for the first-line therapy of patients with advanced
disease (Loehrer et al., 1986; Harstrick et al., 1991;
Bokemeyer & Schmoll, 1993). With the increasing clinical use
in this disease it is a very important result that in a pre-
clinical in vivo model with defined experimental conditions
the use of mesna at concentrations ranging from 50% to
200% of that of the dose of ifosfamide does not interfere
with the anti-tumour activity of ifosfamide, at least in testi-
cular cancer xenografts. Although complete combination
crossover dose-response curves of ifosfamide and mesna
would have been necessary to definitely exclude any influence
of mesna on ifosfamide anti-tumour activity, the data pre-
sented here appear sufficiently safe enough to exclude
clinically relevant facts. Despite these limitations it may be
suitable for influencing different dose intensities and dose
escalations within clinical trials.
However, the results gained in the present study are parti-
cularly valid for the application of mesna before and after
the end of ifosfamide therapy, since this schedule is used
clinically because of the long half-life of ifosfamide
metabolites in the urine in comparison with a rather short
Days
Figure 1 Growth kinetics of heterotransplanted testicular cancer
cell line H 12.1 treated by different schedules of ifosfamide and
mesna (rTA = relative tumour area in comparison with untreated
controls at day 0). *, Ifosfamide 50 mg kg-' day-' i.p.; 0,
ifosfamide 50 mg kg-' day-' i.p. + mesna 50mg kg-' day-' i.p.;
*, control; A, ifosfamide 50mg kg-'day-' i.p. + 2 x mesna
25 mgkg-' day-' i.p. (at 0 and 3 h); A, ifosfamide
50mg kg-' day-' i.p. + 2 x mesna 50mg kg-' day-' i.p. (at 0
and 3h) on days 1-4 and 15-18.
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Figure 2 Growth kinetics ofheterotransplanted testicular cancer
cell line 2102 EP in nude mice after therapy with different
schedules of ifosfamide alone and in combination with mesna
application. *, Ifosfamide 50mg kg-' day-' i.p.; 0, control; A,
ifosfamide 50mg kg-' day-' i.p. + 2 x mesna 50mgkg-' day-'
i.p. (at 0 and 3h) on days 1-4 and 15-18.
half-life of mesna after intravenous application. The preven-
tion of bladder toxicity of ifosfamide without any impair-
ment of anti-tumour activity by mesna may also be important
in view of recent results from phase I/II studies indicating
that dose escalation of ifosfamide in patients refractory to
standard doses of ifosfamide may be able to achieve clinical
responses (Elias et al., 1990).
Different investigators have raised concern about a
decreased activity of ifosfamide or cyclophosphamide when
given in combination with mesna. Wagner et al. (1974)
na
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reported a 50% reduced therapeutic activity of cyclophos-
phamide in L1210 leukaemia cells heterotransplanted into
DBA2 mice when co-administered with mesna. Willemse and
de Vries (1989) discussed the problem of reduced ifosfamide
activity when combined with a high-dose continuous infusion
of mesna compared with single-bolus application mesna in
patients with metastatic sarcoma. Two mechanisms have
been proposed which might be possibly relevant when con-
tinuous high doses (greater than or equal to the dose of
ifosfamide) are used:
1. The presence of mesna together with ifosfamide in the
blood circulation may inactivate the active drug
metabolites 4-hydroxyifosfamide and ifosfamide mustard
by the formation of thioethers.
2. In vitro studies have shown that the toxic but non-
cytostatic ifosfamide metabolite acrolein binds SH groups,
thereby reducing the thiol-binding capacity of the cell.
This depletion of SH groups may enhance the alkylating
potential of other active metabolites with anti-tumour
activity. The presence of mesna might reduce this syner-
gistic potentiating effect of acrolein, thereby reducing the
cytotoxic activity (Crook et al., 1986; Shaw & Graham,
1987). Others have questioned the quantitative importance
of these reactions, but have also proposed to use mesna in
the lowest dose that adequately protects the urinary tract
(Antman & Elias, 1989).
The use of other substances as selective uroprotective
agents has been addressed in different clinical studies. How-
ever, many agents investigated, such as carboxycysteine,
disulphiram, glutathione, WR 2721 and N-acetylcysteine, are
mainly cleared from the blood plasma via distribution
throughout the tissues and intracellular uptake and the pro-
portion of renal excretion is small. Only a few agents, such as
mesna and dimesna, are excreted through the urine (Brock et
al., 1984). Two large trials have compared the uroprotective
potential of N-acetylcysteine versus mesna in patients with
soft-tissue sarcomas and germ cell tumours (Munshi et al.,
1992; Benjamin et al., 1993). Both studies demonstrated
significantly superior results for mesna as a uroprotective
agent.
Two additional aspects of mesna application may be
important during ifosfamide therapy: in patients undergoing
high-dose ifosfamide regimens mesna may not only be able to
protect from urothelial toxicity but might also positively
influence the incidence of ifosfamide-related central nervous
toxicity (Cerny & Kiipfer, 1992). Furthermore, the applica-
tion of mesna may not only prevent acute urothelial damage
and haematuria but might also be able to reduce the risk for
the occurrence of bladder cancer following cyclophosphamide
and ifosfamide therapy (Richie, 1984). In vitro results and
early clinical trials in patients with superficial bladder cancer
have even demonstrated activity of mesna itself as cytotoxic
treatment in bladder cancer. Different bladder cancer cell
lines were found to be sensitive upon repeated administra-
tions of mesna (Blomgren et al., 1991). The prevention of
secondary bladder cancer following oxazophosphorine
therapy may be particularly relevant for patients who have a
great chance of cure for their primary tumour and who will
have a long disease-free life expectancy, such as patients with
testicular cancer.
When prophylactic agents are used during chemotherapy
for the prevention of specific side-effects caused by the
cytotoxic treatment it remains an important issue to prove by
the use of adequate tumour models that these prophylactic
agents do not interfere with the anti-tumour activity of the
cytostatic agent used. Although the number of mice used in
the study presented here allows only a limited interpretation
of the results without a large statistical analysis, the
experiments in two heterotransplanted human testicular
cancer cell lines in nude mice show that the application of
mesna at clinically used dosages and schedules does not
compromise the anti-tumour activity of the oxazaphos-
phorine derivative ifosfamide. These results may also be
relevant for the treatment of other types of cancer with
ifosfamide.
The author's would like to thank D. Reile for skilful technical help
with the cell culture work.
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